Grufity logo
Grufity logo
AADI

AADI - Aadi Bioscience, Inc. Stock Price, Fair Value and News

$12275.00-175.00 (-1.41%)
Market Closed as of 10 Sep 2026, 04:00 pm ET

AADI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AADI Price Action

Last 7 days

9.8%

Last 30 days

33.1%

Last 90 days

41.9%

Trailing 12 Months

75.4%

AADI RSI Chart

AADI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AADI Valuation

Market Cap

699.8B

Price/Earnings (Trailing)

-8.8K

Price/Sales (Trailing)

71.4K

EV/EBITDA

-24.8K

Price/Free Cashflow

-10.1K

AADI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AADI Fundamentals

AADI Revenue

Revenue (TTM)

7.1M

Rev. Growth (Yr)

-100%

AADI Earnings

Earnings (TTM)

-79.8M

Earnings Growth (Yr)

68.37%

Earnings Growth (Qtr)

25.02%

AADI Profitability

EBT Margin

-288.26%

Return on Equity

-43.64%

Return on Assets

-41.15%

Free Cashflow Yield

-0.01%

AADI Investor Care

Shares Dilution (1Y)

20.97%

Diluted EPS (TTM)

-1.53

Revenue & Growth

How Aadi Bioscience, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
202527.8M21.6M14.4M7.1M
202423.8M23.8M25.1M26.0M
202318.8M21.5M23.3M24.4M
202214.3M14.6M14.9M15.2M
202114.0M14.0M14.0M14.0M
202018.6M17.1M15.5M14.0M
2018-6.8M13.5M20.2M
2017158.3K88.6K108.8K93.7K
2016310.1K250.5K190.9K131.3K
2015---369.7K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Aadi Bioscience, Inc.

AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
 CEO
 WEBSITEhttps://aadibio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES89

Aadi Bioscience, Inc. Frequently Asked Questions

AADI is the stock ticker symbol of Aadi Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 10 2026, market cap of Aadi Bioscience, Inc. is 699.79 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Sep 10 2026, AADI's PE ratio (Price to Earnings) is -8765.84 and Price to Sales (PS) ratio is 71.41 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AADI PE ratio will change depending on the future growth rate expectations of investors.